PODD Stock Forecast 2025-2026
Distance to PODD Price Targets
PODD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Insulet (PODD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PODD and similar high-potential opportunities.
Latest PODD Stock Price Targets & Analyst Predictions
Based on our analysis of 32 Wall Street analysts, PODD has a bullish consensus with a median price target of $320.00 (ranging from $234.00 to $350.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $246.80, the median forecast implies a 29.7% upside. This outlook is supported by 20 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jayson Bedford at Raymond James, projecting a 41.8% upside. Conversely, the most conservative target is provided by Matt Miksic at Barclays, suggesting a 5.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PODD Analyst Ratings
PODD Price Target Range
Latest PODD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PODD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2025 | RBC Capital | Shagun Singh | Outperform | Initiates | $340.00 |
| Feb 21, 2025 | Citigroup | Joanne Wuensch | Buy | Maintains | $355.00 |
| Feb 21, 2025 | Wells Fargo | Lawrence Biegelsen | Overweight | Maintains | $322.00 |
| Feb 21, 2025 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $310.00 |
| Feb 21, 2025 | Stifel | Mathew Blackman | Hold | Maintains | $293.00 |
| Feb 21, 2025 | Raymond James | Jayson Bedford | Outperform | Reiterates | $328.00 |
| Feb 21, 2025 | Canaccord Genuity | Kyle Rose | Buy | Maintains | $324.00 |
| Jan 3, 2025 | TD Cowen | Joshua Jennings | Buy | Maintains | $324.00 |
| Dec 12, 2024 | JP Morgan | Robbie Marcus | Overweight | Maintains | $330.00 |
| Dec 11, 2024 | Wells Fargo | Lawrence Biegelsen | Overweight | Maintains | $305.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $310.00 |
| Dec 9, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $304.00 |
| Nov 11, 2024 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $317.00 |
| Nov 11, 2024 | Barclays | Matt Miksic | Equal-Weight | Maintains | $234.00 |
| Nov 8, 2024 | BTIG | Marie Thibault | Buy | Maintains | $270.00 |
| Nov 6, 2024 | Bernstein | Lee Hambright | Outperform | Initiates | $300.00 |
| Oct 14, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $260.00 |
| Oct 14, 2024 | BTIG | Marie Thibault | Buy | Maintains | $260.00 |
| Oct 1, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $275.00 |
| Sep 25, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $269.00 |
Insulet Corporation (PODD) Competitors
The following stocks are similar to Insulet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Insulet Corporation (PODD) Financial Data
Insulet Corporation has a market capitalization of $17.33B with a P/E ratio of 42.7x. The company generates $2.07B in trailing twelve-month revenue with a 20.2% profit margin.
Revenue growth is +17.2% quarter-over-quarter, while maintaining an operating margin of +16.0% and return on equity of +43.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Insulet Corporation (PODD) Business Model
About Insulet Corporation
Develops innovative devices for diabetes management.
Insulet Corporation generates revenue primarily through the sales of its Omnipod Insulin Management System, a tubeless insulin pump designed for diabetes management. The company targets healthcare providers and patients, creating a continuous stream of income from both product sales and recurring consumables associated with the insulin delivery system.
Headquartered in Acton, Massachusetts, Insulet is focused on enhancing patient experiences and outcomes while supporting healthcare providers. The company's commitment to innovation and accessibility positions it as a leader in the medical technology industry, particularly in insulin delivery solutions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
3,900
CEO
Dr. James R. Hollingshead Ph.D.
Country
United States
IPO Year
2007
Website
www.insulet.comInsulet Corporation (PODD) Latest News & Analysis
U.S. tariffs on China may pressure supply chains in the Zacks Medical Products industry, benefiting companies like PODD, MGNX, CLRB, and ALUR.
Tariffs on China may strain supply chains, impacting costs in the medical products sector. Companies like PODD, MGNX, CLRB, and ALUR could benefit from this market shift.
Insulet has launched the Omnipod 5 AID system in Canada, which is compatible with Dexcom G6 and G7 CGM sensors.
Insulet's launch of the Omnipod 5 AID system in Canada enhances its product offering and market reach, potentially driving revenue growth and increasing competitive advantage in diabetes management.
Insulet (PODD) experienced significant trading volume recently. However, recent earnings estimate revisions may hinder its upward momentum.
Insulet's high trading volume and concerning earnings estimate revisions suggest potential volatility, indicating caution for investors considering the stock's future performance.
Five stocks—SFM, UNH, SRAD, GME, and PODD—have delivered over 4% returns in the past month, despite experiencing extreme volatility.
The mention of five stocks delivering over 4% returns amidst volatility signals potential resilience and opportunity for short-term gains, attracting investor interest.
This Insulin Pump Maker Expands Into New Territory And Its Stock Shows Relative Strength
12 days agoInsulet's stock is in a base pattern, with its relative strength line reaching a 52-week high. The company's insulin pump is now available in Canada.
The stock's base formation and strong relative strength indicate potential upward momentum, while the Canadian launch of Insulet's insulin pump could drive revenue growth.
Insulet Corporation (NASDAQ: PODD) will release Q1 2025 financial results on May 8, 2025, after market close, followed by a conference call at 4:30 p.m. ET.
Insulet's upcoming financial results release could impact stock prices, reflecting the company's performance and growth potential in the insulin pump market, influencing investment decisions.
Frequently Asked Questions About PODD Stock
What is Insulet Corporation's (PODD) stock forecast for 2025?
Based on our analysis of 32 Wall Street analysts, Insulet Corporation (PODD) has a median price target of $320.00. The highest price target is $350.00 and the lowest is $234.00.
Is PODD stock a good investment in 2025?
According to current analyst ratings, PODD has 20 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $246.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PODD stock?
Wall Street analysts predict PODD stock could reach $320.00 in the next 12 months. This represents a 29.7% increase from the current price of $246.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Insulet Corporation's business model?
Insulet Corporation generates revenue primarily through the sales of its Omnipod Insulin Management System, a tubeless insulin pump designed for diabetes management. The company targets healthcare providers and patients, creating a continuous stream of income from both product sales and recurring consumables associated with the insulin delivery system.
What is the highest forecasted price for PODD Insulet Corporation?
The highest price target for PODD is $350.00 from Jayson Bedford at Raymond James, which represents a 41.8% increase from the current price of $246.80.
What is the lowest forecasted price for PODD Insulet Corporation?
The lowest price target for PODD is $234.00 from Matt Miksic at Barclays, which represents a -5.2% decrease from the current price of $246.80.
What is the overall PODD consensus from analysts for Insulet Corporation?
The overall analyst consensus for PODD is bullish. Out of 32 Wall Street analysts, 20 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $320.00.
How accurate are PODD stock price projections?
Stock price projections, including those for Insulet Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.